(Q46494275)

22 December 2017

title

12-month observation of testosterone replacement effectiveness in a general population of men. (English)

1 reference

22 December 2017

1 reference

1 reference

Martin M Miner

1

1 reference

22 December 2017

Rajib K Bhattacharya

2

1 reference

22 December 2017

Gary Blick

3

1 reference

22 December 2017

Harvey Kushner

4

1 reference

22 December 2017

Mohit Khera

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

22 December 2017

published in

Postgraduate Medicine

1 reference

22 December 2017

volume

125

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

8-18

1 reference

22 December 2017

Prevalence of hypogonadism in males aged at least 45 years: the HIM study

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Time for international action on treating testosterone deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Androgens, health and sexuality in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

The PHQ-9: validity of a brief depression severity measure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Monitoring depression treatment outcomes with the patient health questionnaire-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Onset of effects of testosterone treatment and time span until maximum effects are achieved

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Blood testosterone threshold for androgen deficiency symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

Distribution of the Brief Male Sexual Inventory in community men

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.03.2637

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.03.2637

1 reference

22 December 2017

1 reference

22 December 2017